Home Services Regulatory Affairs

news011

Pending Litigation to Delay Launch of Generic Asacol


Boehringer Ingelheim’s Roxane Laboratories will postpone until at least November planned sales of its generic version of Asacol, an ulcerative colitis drug, to resolve a patent infringement suit over the drug. In a deal reached recently with Procter & Gamble Pharmaceuticals and Medeva Pharma Suisse — the brand manufacturers of Asacol (mesalamine) — Roxane agreed to delay the drug’s launch to extend the trial’s discovery phase in the U.S. District Court for the District of New Jersey.
Generic Line

News & Events

  • GSK Receives EMEA Approval for Duodart LONDON (AP) - Pharmaceutical company GlaxoSmithKline... Read more>>
  • T Cell Proliferation Assays ProImmune Ltd, a leader in epitope discovery, immunogenicity, an... Read more>>
  • Statins May Slow Progression Of Multiple Sclerosis, New Study Finds A UCSF-led study exa... Read more>>
  • FDA Approves Mylan’s Drug Applications Mylan Inc. Monday announced that its subsidiary Mylan Ph... Read more>>
  • Proximagen Signs Deal With Upsher-Smith Proximagen Neuroscience plc, a biotechnology company... Read more>>
  • Novozymes Partnering With ProMetic Life Sciences Inc.Drug Discovery & Development - April 0... Read more>>
  • New Class of Brain-Protecting Drugs Emerging Researchers have identified a compound that mim... Read more>>
  • U.S. Food & Drug Administration (FDA) New and Generic Drug Approvals Calan (verapamil h... Read more>>
  • in vivo Pharmacodynamic Assay Trevigen offers a validated assay with higher sensitivity and... Read more>>
  • Mapping Technique Speeds Finding Specific Genes A Purdue University scientist was part of a... Read more>>
  • Food and Drug Administration NOTICES Meetings:   Internationa... Read more>>
  • FDA Requests More Information on Certriad LONDON (AP) - AstraZeneca PLC and Abbott Laborator... Read more>>